International Edition
Latest News
Health

Serum Protein Electrophoresis Tracks Therapeutic Recovery in FIP Cats Treated with Remdesivir

A prospective clinical investigation has demonstrated that serial serum protein electrophoresis reliably tracks therapeutic recovery in cats treated for feline infectious peritonitis with remdesivir, according to findings published in Veterinary Medicine and Science. The study, conducted under institutional…

A prospective clinical investigation has demonstrated that serial serum protein electrophoresis reliably tracks therapeutic recovery in cats treated for feline infectious peritonitis with remdesivir, according to findings published in Veterinary Medicine and Science.

The study, conducted under institutional Animal Ethics Committee approval, enrolled 18 client-owned cats with confirmed FIP and treated them with a standardized four-week remdesivir protocol manufactured by Actoverco Pharmaceutical Company. All 18 cats achieved complete clinical remission that persisted through a 60-day post-treatment observation period with no mortality, the researchers reported.

FIP, a historically fatal disease caused by virulent mutations of feline coronavirus, has lacked objective biomarkers to evaluate antiviral response and optimize treatment duration. The research team, led by investigators at a veterinary clinic in Iran, sought to determine whether serial measurements of serum protein fractions — specifically reductions in gamma-globulins and elevations in the albumin-to-globulin (A/G) ratio — could serve as prognostic aids during remdesivir therapy.

Cats received remdesivir at 10 mg/kg intravenously once daily for the first five days, followed by subcutaneous injection every 24 hours for the remainder of the 28-day period. Supportive care included fluid therapy, amoxicillin, and anti-inflammatory prednisolone.

Clinical improvement was evident by the second week, with resolution of lethargy, inappetence, weight loss, and cavitary effusions. At baseline, 17 cats exhibited lethargy, 16 had abdominal effusion or ascites, 16 showed ventral and subcutaneous edema, 16 presented with fever exceeding 39.5 °C, eight had concurrent vomiting and diarrhea, six had pleural effusion, and two displayed neurological deficits.

Repeated blood tests showed the anemia largely cleared. The cohort mean red blood cell count increased from 3.9 ± 0.6 × 10⁶/µL at baseline to 5.9 ± 0.8 × 10⁶/µL by week four (p < 0.05). Mean hematocrit rose from 27.7 ± 2.9% to 39.2 ± 2.6% over the same period.

Liver inflammation markers dropped. Mean alanine aminotransferase (ALT) activity dropped from 151 ± 34 U/L to 68 ± 26 U/L by week four. Renal parameters — blood urea nitrogen, serum creatinine, and alkaline phosphatase — remained within normal reference intervals throughout the study, indicating no observable nephrotoxicity or drug-induced hepatocellular injury.

Serum protein electrophoresis, performed on an automated Sebia Hydrasys system using HYDRAGEL 7 PROTEIN agarose gels, documented dramatic recalibration of circulating protein fractions.

Total serum protein decreased significantly from 9.12 ± 0.84 g/dL to 6.85 ± 0.52 g/dL (p < 0.001), while absolute serum albumin climbed from 2.14 ± 0.31 g/dL to 3.28 ± 0.29 g/dL. Every cat exceeded the critical A/G ratio threshold of 0.55 by the end of active therapy.

The most striking change occurred in the gamma-globulin fraction, which fell from a baseline mean of 42.5 ± 4.8% to 18.4 ± 2.1% by week four (p < 0.001). Alpha-globulins decreased from 18.2 ± 2.1% to 12.1 ± 1.4%, with alpha-2-globulins showing significant reduction (p = 0.0305). Beta-globulins, predominantly the beta-2 subfraction, exhibited a relative compensatory increase.

Representative densitometric electrophoretograms showed a progressive longitudinal shift from severe polyclonal hypergammaglobulinemia and blunted albumin peaks at baseline toward early gamma-peak regression by week one and complete normalization by week four.

Receiver operating characteristic (ROC) curve analyses substantiated the discriminatory accuracy of electrophoretic parameters for evaluating therapeutic progress. Diagnostic accuracy of the A/G ratio increased steadily across paired time intervals, reaching its zenith when comparing week one against baseline and week four against week one.

The researchers concluded that serial serum protein electrophoresis provides continuous, objective time-course data detailing dynamic changes in protein fractions, precisely mirroring systemic viral clearance and disease resolution during remdesivir therapy.

The study was published online ahead of print in Veterinary Medicine and Science (DOI: 10.1002/vms3.71347).

About the author: Health Desk

Health Desk at Archynewsy.